Role of Anti- Müllerian Hormone in Pathogenesis, Diagnosis and Treatment of Polycystic Ovary Syndrome

doi:10.12280/gjfckx.20230141

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is a relatively common female reproductive endocrine and metabolic disorder with complex etiology and pathogenesis. Recent studies have found that anti-Müllerian hormone (AMH) is an important factor affecting the pathophysiology of PCOS. AMH is closely related to follicular development, hyperandrogenism, hypothalamic-pituitary-ovarian axis and heredity. AMH can inhibit primordial follicle recruitment and small sinus follicle growth, and prevent premature ovarian failure. AMH also exacerbates follicular growth and development disorders by interacting with androgens. In addition, AMH can activate the discharge of gonadotropin-releasing hormone (GnRH) neurons and increases the secretion of luteinizing hormone (LH), which in turn leads to the increase of androgen production. Moreover, high AMH status in pregnant women with PCOS can lead to masculinization of female offspring and PCOS-like reproductive and neuroendocrine phenotypes in adulthood. At the same time, AMH may also be a new indicator for the diagnosis of PCOS, and the determination of AMH level can also reflect and predict the therapeutic effect of PCOS patients.

Key words: Polycystic ovary syndrome, Anti-mullerian hormone, Ovulation, Hyperandrogenism, Diagnosis, Therapy

GAO Ya, LU Di, SONG Dian-rong. Role of Anti- Müllerian Hormone in Pathogenesis, Diagnosis and Treatment of Polycystic Ovary Syndrome[J]. Journal of International Obstetrics and Gynecology, 2023, 50(5): 540-544.

References 39

[1]	Xu Y, Qiao J. Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature[J]. J Healthc Eng, 2022, 2022:9240569. doi: 10.1155/2022/9240569.
[2]	Moolhuijsen L, Louwers YV, Laven J, et al. Comparison of 3 Different AMH Assays With AMH Levels and Follicle Count in Women With Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2022, 107(9):e3714-e3722. doi: 10.1210/clinem/dgac370. pmid: 35737957
[3]	丁芳, 易晓芳. 血清抗苗勒管激素和胰岛素样生长因子-1与多囊卵巢综合征的相关研究[J]. 中国临床研究, 2022, 35(12):1658-1661. doi: 10.13429/j.cnki.cjcr.2022.12.005.
[4]	Silva M, Giacobini P. New insights into anti-Müllerian hormone role in the hypothalamic-pituitary-gonadal axis and neuroendocrine development[J]. Cell Mol Life Sci, 2021, 78(1):1-16. doi: 10.1007/s00018-020-03576-x.
[5]	Chauvin M, Garambois V, Choblet S, et al. Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival[J]. Int J Oncol, 2021, 59(1):43. doi: 10.3892/ijo.2021.5223.
[6]	赵倩, 周抒. 抗苗勒管激素与多囊卵巢综合征的关系[J]. 国际妇产科学杂志, 2022, 49(6):659-663. doi: 10.12280/gjfckx.20220217.
[7]	Rey R, Lukas-Croisier C, Lasala C, et al. AMH/MIS: what we know already about the gene, the protein and its regulation[J]. Mol Cell Endocrinol, 2003, 211(1/2):21-31. doi: 10.1016/j.mce.2003.09.007.
[8]	Moses MM, Behringer RR. A gene regulatory network for Müllerian duct regression[J]. Environ Epigenet, 2019, 5(3):dvz017. doi: 10.1093/eep/dvz017.
[9]	Gagliardi F, Lauro A, De Anna L, et al. The Risk of Malignant Degeneration of Müllerian Derivatives in PMDS: A Review of the Literature[J]. J Clin Med, 2023, 12(9):3115. doi: 10.3390/jcm12093115.
[10]	Xu H, Zhang M, Zhang H, et al. Clinical Applications of Serum Anti-Müllerian Hormone Measurements in Both Males and Females: An Update[J]. Innovation(Camb), 2021, 2(1):100091. doi: 10.1016/j.xinn.2021.100091.
[11]	Kostrzewa M, Głowacka E, Stetkiewicz T, et al. Is serum anti-Müllerian hormone(AMH) assay a satisfactory measure for ovarian reserve estimation? A comparison of serum and peritoneal fluid AMH levels[J]. Adv Clin Exp Med, 2020, 29(7):853-856. doi: 10.17219/acem/121010. pmid: 32735089
[12]	Durlinger AL, Kramer P, Karels B, et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary[J]. Endocrinology, 1999, 140(12):5789-5796. doi: 10.1210/endo.140.12.7204. pmid: 10579345
[13]	Kataoka J, Larsson I, Lindgren E, et al. Circulating Anti-Müllerian hormone in a cohort-study of women with severe obesity with and without polycystic ovary syndrome and the effect of a one-year weight loss intervention[J]. Reprod Biol Endocrinol, 2022, 20(1):153. doi: 10.1186/s12958-022-01022-0.
[14]	Huang SJ, Purevsuren L, Jin F, et al. Effect of anti-müllerian hormone on the development and selection of ovarian follicle in hens[J]. Poult Sci, 2021, 100(3):100959. doi: 10.1016/j.psj.2020.12.056.
[15]	Shi Y, Li L, Zhou J, et al. Efficacy of electroacupuncture in regulating the imbalance of AMH and FSH to improve follicle development and hyperandrogenism in PCOS rats[J]. Biomed Pharmacother, 2019, 113:108687. doi: 10.1016/j.biopha.2019.108687.
[16]	Chen M, Guo X, Zhong Y, et al. AMH inhibits androgen production in human theca cells[J]. J Steroid Biochem Mol Biol, 2023, 226:106216. doi: 10.1016/j.jsbmb.2022.106216.
[17]	Kim JY, Tfayli H, Michaliszyn SF, et al. Anti-Müllerian Hormone in Obese Adolescent Girls With Polycystic Ovary Syndrome[J]. J Adolesc Health, 2017, 60(3):333-339. doi: 10.1016/j.jadohealth.2016.10.015. pmid: 27998701
[18]	Li Y, Zhai Y, Li L, et al. Divergent Associations Between Serum Androgens and Ovarian Reserve Markers Revealed in Patients With Polycystic Ovary Syndrome[J]. Front Endocrinol(Lausanne), 2022, 13:881740. doi: 10.3389/fendo.2022.881740.
[19]	Sumji S, Bhat A, Rashid A, et al. Efficacy of serum anti-mullerian hormone (AMH) levels for prediction of polycystic ovary syndrome (PCOS) and its association with clinical, biochemical and hormonal parameters[J]. Ind J Clin Biochem, 2022, 37:1-9. doi: 10.1007/s12291-022-01058-4.
[20]	Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest[J]. Hum Reprod Update, 2004, 10(2):107-117. doi: 10.1093/humupd/dmh010. pmid: 15073141
[21]	李蓉, 曾玖芝. 血清抗苗勒管激素在多囊卵巢综合征诊断中的应用价值[J]. 实用医院临床杂志, 2021, 18(5):216-219. doi: 10.3969/j.issn.1672-6170.2021.05.059.
[22]	Cimino I, Casoni F, Liu X, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion[J]. Nat Commun, 2016, 7:10055. doi: 10.1038/ncomms10055. pmid: 26753790
[23]	Barbotin AL, Mimouni N, Kuchcinski G, et al. Hypothalamic neuroglial plasticity is regulated by anti-Müllerian hormone and disrupted in polycystic ovary syndrome[J]. EBioMedicine, 2023, 90:104535. doi: 10.1016/j.ebiom.2023.104535.
[24]	Rudnicka E, Kunicki M, Calik-Ksepka A, et al. Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS[J]. Int J Mol Sci, 2021, 22(22):12507. doi: 10.3390/ijms222212507.
[25]	Garrel G, Denoyelle C, L′Hôte D, et al. GnRH Transactivates Human AMH Receptor Gene via Egr1 and FOXO1 in Gonadotrope Cells[J]. Neuroendocrinology, 2019, 108(2):65-83. doi: 10.1159/000494890. pmid: 30368511
[26]	Raperport C, Homburg R. The source of polycystic ovarian syndrome[J]. Clin Med Insights Reprod Health, 2019, 13:1179558119871467. doi: 10.1177/1179558119871467.
[27]	Tata B, Mimouni N, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood[J]. Nat Med, 2018, 24(6):834-846. doi: 10.1038/s41591-018-0035-5. pmid: 29760445
[28]	Cianci A, Vitale SG. D-Chiro-inositol and PCOS: between myth and reality. The never-ending story[J]. Int J Food Sci Nutr, 2022, 73(5):565-570. doi: 10.1080/09637486.2022.2029830.
[29]	Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH[J]. Asian Pac J Cancer Prev, 2017, 18(1):17-21. doi: 10.22034/APJCP.2017.18.1.17.
[30]	Dewailly D. Diagnostic criteria for PCOS: Is there a need for a rethink?[J]. Best Pract Res Clin Obstet Gynaecol, 2016, 37:5-11. doi: 10.1016/j.bpobgyn.2016.03.009. pmid: 27151631
[31]	Jarrett BY, Vanden Brink H, Oldfield AL, et al. Ultrasound Characterization of Disordered Antral Follicle Development in Women with Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2020, 105(11):e3847-e3861. doi: 10.1210/clinem/dgaa515.
[32]	Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data[J]. J Clin Endocrinol Metab, 2013, 98(8):3332-3340. doi: 10.1210/jc.2013-1393. pmid: 23775353
[33]	Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?[J]. Hum Reprod, 2012, 27(8):2494-2502. doi: 10.1093/humrep/des213.
[34]	Teede H, Misso M, Tassone EC, et al. Anti-Müllerian Hormone in PCOS: A Review Informing International Guidelines[J]. Trends Endocrinol Metab, 2019, 30(7):467-478. doi: 10.1016/j.tem.2019.04.006.
[35]	Daneshjou D, Mehranjani MS, Zadehmodarres S, et al. Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: A new alternative to metformin (a randomized trial)[J]. J Reprod Immunol, 2022, 150:103499. doi: 10.1016/j.jri.2022.103499.
[36]	王春红, 王强强, 苏亚珊, 等. 二甲双胍改善多囊卵巢综合征并激活雌性生殖干细胞[J]. 生理学报, 2022, 74(3):370-380. doi: 10.13294/j.aps.2021.0090.
[37]	Yin WW, Huang CC, Chen YR, et al. The effect of medication on serum anti-müllerian hormone(AMH) levels in women of reproductive age: a meta-analysis[J]. BMC Endocr Disord, 2022, 22(1):158. doi: 10.1186/s12902-022-01065-9.
[38]	Gülşen MS, Ulu İ, Yıldırım KŞ et al. The role of anti-Müllerian hormone in predicting clomiphene citrate resistance in women with polycystic ovarian syndrome[J]. Gynecol Endocrinol, 2019, 35(1):86-89. doi: 10.1080/09513590.2018.1499085. pmid: 30044165
[39]	Ocal P, Sahmay S, Cetin M, et al. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles[J]. J Assist Reprod Genet, 2011, 28(12):1197-1203. doi: 10.1007/s10815-011-9627-4.